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Cytogenetic alterations form the basis for risk stratification for multiple
myeloma (MM) and guide the selection of therapy; however, current
pathology assays performed on bone marrow samples can produce false-
negatives due to the unpredictable distribution and rarity of MM cells.
Here, we report on a microfluidic device used to facilitate CD45 depletion
to enhance the detection of cytogenetic alterations in plasma cells (PCs).
Bone marrow samples from 48 patients with MM were each divided into
two aliquots. One aliquot was subjected to classic flow cytometry and fluo-
rescent in situ hybridization (FISH). The other first went through CD45+
cell depletion, further enriched by microfluidic size selection. The enriched
samples were then analyzed using flow cytometry and FISH and compared
to those analyzed using the classic method only. Unlike the traditional
method, the microfluidic device removed the CD45+ leukocytes and specif-
ically selected PCs from the remaining white blood cells. Therefore, the
microfluidic method (MF-CD45-TACs) significantly increased the percent-
age of CD38+/CD138+ cells to 37.7  20.4% (P < 0.001) from 10.3 
8.5% in bone marrow. After the MF-CD45-TAC enrichment, the detection
rate of IgH rearrangement, del(13q14), del(17p), and 1q21 gains, rose to
56.3% (P < 0.001), 37.5% (P < 0.001), 22.9% (P < 0.001), and 41.7%
(P = 0.001), respectively; all rates of detection were significantly increased
compared to the classically analyzed samples. In this clinical trial, this
microfluidic-assisted assay provided a precise detection of cytogenetic alter-
ations in PCs and improved clinical outcomes.
1. Introduction
Multiple myeloma (MM) is an incurable neoplasm of
plasma cells (PCs) that affects more than 20 000
people annually in the United States. Risk stratifica-
tion, primarily based on cytogenetic abnormalities, has
emerged as essential for its management (Mikhael
et al., 2013). Thalidomide, lenalidomide, and
Abbreviations
AJH, American Journal of Hematology; DLD, deterministic lateral displacement; FACS, fluorescence-activated cell sorting; FISH, fluorescent
in situ hybridization; IMWG, International Myeloma Working Group; MACS, magnetic-activated cell sorting; MF-CD45-TACs, microfluidic–
CD45 depletion–tetrameric antibody complexes; MM, multiple myeloma; PCs, plasma cells; PDMS, polydimethylsiloxane; TACs, tetrameric
antibody complexes; VRD, bortezomib, lenalidomide, and dexamethasone; VTD, bortezomib, thalidomide, and dexamethasone.
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pomalidomide, which represent the first to third gener-
ations of immunomodulatory drugs, respectively, are
used for MM maintenance therapy. Cytogenetic alter-
ations form the basis of MM risk stratification and
selection of immunomodulatory drugs for therapy
(Nathwani et al., 2016). PCs undergo clonal evolution:
In earlier and smoldering disease, CD45-positive cells
predominate, whereas CD45-negative PCs are more
prevalent in patients with advanced disease (both new
and relapsed) (Kumar et al., 2005). Thus, both CD45
and CD45+ can serve as prognostic biomarkers for
MM (Gonsalves et al., 2016) but with distinct prog-
noses. The tumor load in patients with CD45 cells is
higher than those with CD45+ cells, which could be
explained by the lower proliferation rate of the latter
population (Asosingh et al., 2001). Malignant PCs
manifest as CD45 cells with co-expression of CD38/
CD138 plus CD19 and CD56, implying the clinical sig-
nificance of CD45 cells in risk stratification of MM
(Langer et al., 2016). Therefore, depletion of CD45+
cells in bone marrow could enrich PCs for this pur-
pose.
The rarity and sporadic distribution of PCs in bone
marrow often leads to false-negative results when fluo-
rescence-activated cell sorting (FACS) or cytogenetic
detection is performed directly on a bone marrow
biopsy sample. Also, morphologic heterogeneity and
cytogenetic heterogeneity affect the flow cytometric
recovery of PCs in bone marrow aspirates of patients
with MM (Cogbill et al. 2015), resulting in inconsistent
biomarker profiles (Kim et al. 2012) and affecting treat-
ment decisions (Nadav et al. 2006). Improving the sen-
sitivity and precision of MM diagnosis could therefore
significantly impact clinical outcomes.
Target cell enrichment could overcome the rarity and
sporadic distribution of PCs in bone marrow. Density
gradient centrifugation and magnetically labeled anti-
bodies with magnetic-activated cell sorting (MACS)
have been widely used to enrich target cells in blood
samples. MACS enrichment of CD138+ cells for fluo-
rescent in situ hybridization (FISH) in MM diagnosis
has been reported (Chen et al., 2007). However, MM
cells with low levels of CD138 have also been associated
with poor prognosis.(Kawano et al., 2012) Therefore, a
better enrichment method is needed. Here, we report a
novel microfluidic approach, combining microfluidic
size selection and CD45 depletion with tetrameric anti-
body complexes (TACs) for enrichment of MM cells in
bone marrow samples (MF-CD45-TAC enrichment).
Our study showed that this approach significantly
improves the detection of rare genetic alterations in
PCs. Parallel diagnosis performed for 48 patients
(Fig. 1) showed that the microfluidic enrichment
approach represents a significant improvement over
direct flow cytometry and FISH and leads to more pre-
cise diagnosis and prognosis. Implementation of this
modified diagnostic assay in clinics could improve cur-
rent clinical outcomes of MM.
Fig. 1. Schematic flowchart of study. (A) Consolidated Standards of Reporting Trials (CONSORT) diagram. A total of 63 patients were
screened for eligibility. Only 48 patients were newly diagnosed with MM before receiving any treatment. These patients were enrolled, and
their bone marrow obtained at diagnosis was divided into two aliquots: One aliquot underwent traditional flow cytometry and FISH analysis,
and the other aliquot was subjected to microfluidic selection for enrichment of CD45-PCs, then subjected to flow cytometry and FISH
analysis. Results from both methods were compared. (B) Comparison of traditional method to microfluidic method (MF-CD45-TACs).
MF-CD45-TACs significantly enrich PCs for flow cytometry and FISH assays and improve the accuracy of these assays.
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2. Methods
2.1. Patient enrollment
We enrolled 48 newly diagnosed and untreated
patients with MM in this study. BM samples of
patients were obtained at diagnosis with informed con-
sent. The sample from each patient was divided into
two parts. One part was directly subjected to flow
cytometry and FISH while the other part was pro-
cessed with microfluidic deterministic lateral displace-
ment (DLD) (McGrath et al., 2014) and CD45
depletion with TACs to link CD45+ cells with red
blood cells (Z-genetic medicine, USA). The CD45-
depleted (MF-CD45-TACs) cells were then subjected
to the same FACS and FISH analysis as the classic
assays. The expression of CD38 and CD138 (Ise et al.,
2016; Langer et al., 2016; Matsue et al., 2016) was
detected using flow cytometry (Chen et al., 2016;
Wang et al., 2016). FISH analysis was used to reveal
13q deletion, 17p deletion, IgH rearrangement, and
1q21 gains (Rajkumar, 2016).
2.2. Microfluidic device fabrication
Microfluidic DLD devices were fabricated with stan-
dard photolithography and soft lithography techniques.
Negative photoresist SU8-3025 (Microchem, Westbor-
ough, MA, USA) was used to fabricate the master
mold on a silicon wafer with a photomask. The pat-
terned silicon wafers were silanized with
chlorotrimethylsilane (Aldrich, Burlington, MA, USA)
to facilitate particle desorption mass spectrometry mold
release. Polydimethylsiloxane (PDMS, RTV615; Gen-
eral Electric, USA) mixed with curing agent (5 : 1 w/w
ratio) was poured into the silicon mold and cured at
80 °C for 1 h. Holes were punched for inlet and outlets,
and the PDMS mold was bonded to glass slides after
oxygen plasma treatment. The design of the DLD
device is shown in Fig. 2.
2.3. Microfluidic enrichment of plasma cells
(MF-CD45-TACs)
The microfluidic DLD design consisted of an inlet,
three outlets, and a central flow chamber with microp-
ost array, as shown in Fig. 2. The flow chamber was
35 mm long, 3.5 mm wide, and 30 lm high. The
micropost array was tilted at an angle of 3.2° relative
to the fluid flow direction. For each patient, a 1.0 mL
sample of bone marrow fluid and 500 lL CD45 TACs
were mixed at room temperature for 30 min. The mix-
ture was slowly added into 2.0 mL Ficoll in a test
tube. Low-speed/low-temperature centrifugation was
Fig. 2. Schematic illustration of the microfluidic DLD device. The microfluidic DLD device consists of an inlet, three outlets, and a central
flow chamber with micropost array. The flow chamber is 35 mm long, 3.5 mm wide, and 30 lm high. The micropost array of DLD chip is
tilted at an angle of 3.2° relative to the fluid flow direction to facilitate cell separation.
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performed at 450 g for 15 min. The white film layer at
the interface of the plasma and the Ficoll solution
was transferred to a fresh tube. Then, the white
film layer (50–100 lL, 1 9 106 cells) was loaded
into DLD chip for PC enrichment. The DLD criti-
cal deflection diameter is designed such that large
cells (PCs) flow in a bumping mode and thus are
concentrated in the center of chamber, while small
cells (erythrocytes and most of leukocytes) follow
the mainstream direction. We optimized the design
in the outlet portion to maximize the PC enrich-
ment. The outlet portion of the device consists of a
row of microposts with gradually decreasing gaps.
With this design, although part of the erythrocytes
and leukocytes escaped through the gaps at the
outlet, the PCs can be fully collected once they
were concentrated in the DLD chip. The resulting
DLD-enriched PCs were then subjected to FACS
detection.
2.4. FACS analysis
Samples with or without microfluidic enrichment were
incubated in 20 lL CD20-PerCP, CD38-APC, or
CD138-FITC, for 30 min in the dark at room temper-
ature, and hemolysin was added for 5 min. After being
washed with PBS twice, the supernatant was discarded
upon centrifugation. All reagents were from the BD,
USA, and analysis was performed on BD equipment:
four-color BD FACSCalibur or Six-color BD FACS
Canto II.
2.5. Bone marrow specimen collection and
preparation
Two mililitre bone marrow was collected from each
patient; 5–7 mL PBS was added to each sample and
gently mixed. The mixture was centrifuged at 300 g for
10 min. Eight mililitre 0.075 M KCl solution preheated
to 37 °C (to reduce permeability) was added to the cell
pellets and mixed in a 37 °C hypotonic water bath for
30 min, by gently blowing on the suspended cells 2–3
times. For prefixture, 2 mL immobilized solution
(methanol : glacial acetic acid at a ratio of 3 : 1) was
slowly added to the hypo-osmotic cellular mixture,
which was gently pipetted up and down to make a cell
suspension and centrifuged at 300 g for 10 min. To
the supernatant, 6–8 mL fixative was added and mixed
well. The mixture was allowed to stand for 10 min and
then centrifuged at 300 g for 10 min; this step was
repeated once. The cell suspension was prepared for
slides with the appropriate amount of fixation liquid
and placed at room temperature overnight, followed
by baking at 56 °C for 20 min to 2 h, and then, the
slides were dried and stored at room temperature.
2.6. Fluorescence in situ hybridization (FISH)
The slides prepared as described above were immersed
in a 29 SSC (pH 7.0) solution for 30 min in a 37 °C
water bath. The glass slides were then dehydrated in a
series of 70% ethanol, 85% ethanol, and 100% etha-
nol for 2–3 min each with natural drying. The prepa-
ration of the probe was performed according to the
manufacturer’s manual. The preparation was cen-
trifuged, vortexed and mixed, and again briefly cen-
trifuged. The slide was naturally dried and then placed
in a 56 °C oven to preheat for 5 min. Ten microlitre
probe mixture was dropped onto the hybridization
area of slide and immediately covered with the cover-
slip, followed by sealing the edges with rubber. Bone
marrow samples were denatured at 75 °C for 5 min
and hybridization conditions at 42 °C for 16 h. The
well-sealed slide was subjected to denaturation
hybridization overnight with the hybridization instru-
ment. The coverslip was removed, immediately placed
in 50% formamide/29 SSC washing solution, washed
twice, and rinsed for 10 min, with oscillation 1–3 s in
46 °C water baths. The slide was also washed with 29
SSC solutions and then rinsed for 10 min with oscilla-
tion 1–3 s in a 46 °C water bath. The glass slide was
washed with 0.1% NP-40/29 SSC solution and rinsed
for 5 min, with oscillations of 1–3 s, in a 46 °C water
bath. The glass slide was soaked in 70% ethanol at
room temperature and rinsed for 3 min, then allowed
to dry naturally. The dried glass slide was restained in
the dark by adding 15 lL DAPI counterstain to the
target area and immediately covering with the cover-
slip. The slide was allowed to rest in a dark place for
10–20 min before observations were made.
2.7. Statistical analysis
A paired-samples t-test was used for between-group
comparison of CD38+ CD138+ cells. Comparisons of
13q deletion, 17p deletion, IgH rearrangement, or
1q21 gains were evaluated with paired chi-square tests.
SPSS version 16.0 statistical software (IBM, Armonk,
New York, NY, USA) was used.
3. Results
As an improvement over traditional methods, we
developed a microfluidic method to enrich PCs for
flow cytometry and FISH assays (Fig. 1). As schema-
tized in Fig. 1, the microfluidic method (MF-CD45-
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TACs) significantly increased the percentage of
CD38+/CD138+ cells to 37.7  20.4% (P < 0.001)
from 10.3  8.5% in unmanipulated bone marrow
(Table 1). This indicates that the percentage of PCs
was increased by the depletion of CD45+ cells. The
increase in PC concentration directly impacts the risk
stratification of patients with MM. Before sorting, 11
patients (22.9%) showed evidence of rearrangements
involving the 14q32 region, and deletion of 13q14 was
found in six patients (12.5%). In addition, deletions of
17p and 1q21 gains were, respectively, detected in
three (6.25%) and nine (18.8%) patients. After the
MF-CD45-TAC enrichment, the percentage of
detected IgH rearrangement, del(13q14), del(17p), and
1q21 gains, rose significantly, to 56.3% (P < 0.001 vs.
classic analysis group), 37.5% (P < 0.001), 22.9%
(P < 0.001), and 41.7% (P = 0.001), respectively.
Thus, our microfluidic method (MF-CD45-TACs) can
enrich PCs and significantly increase the detection
rates of genetic aberration in patients with MM.
3.1. Impact of MF-CD45-TACs in clinical
outcomes
In the clinic, MF-CD45-TAC technology has demon-
strated that it can improve diagnosis and change treat-
ment. Based on the International Myeloma Working
Group, bortezomib and carfilzomib improve complete
response, progression-free survival, and overall sur-
vival in t(4;14) and del(17/17p), whereas lenalidomide
may be associated with improved progression-free sur-
vival in t(4;14) and del(17/17p) (Sonneveld et al.,
2016). Therefore, different cytogenetic alterations
require different treatment plan. Patient 1, a 60-year-
old male, was diagnosed with MM, type (IgG, k), ISS
stage III period. No FISH cytogenetic abnormalities
were found using the classic method, leading to low-
risk stratification; however, upon MF-CD45-TAC
enrichment, PCs showed deletion(17p-) and del(13q14)
(Fig. 3), leading to reclassification as high risk. This
diagnosis changed the treatment plan from the initial
VTD (bortezomib, thalidomide, and dexamethasone)
to VRD (bortezomib, lenalidomide, and dexametha-
sone) induction therapy, and this protocol achieved
very good partial remission. After four courses of
autologous stem cell transplantation, the patient
showed complete remission. After another five courses
of VRD consolidation therapy, the patient’s condition
continues to be stable in complete remission with
maintenance RD therapy.
Patient 2, a 41-year-old male, was diagnosed with
MM, (IgG, k) type, ISS stage III period. FISH analy-
sis without microfluidic enrichment showed del(13q14)
and IgH rearrangement. After MF-CD45-TAC enrich-
ment, FISH analysis showed not only these two cyto-
genetic abnormalities, but also del(17p), leading to a
shift from intermediate-risk to high-risk stratification
(Fig. 4). After the patient received four cycles of VTD
regimen and reached very good partial remission, his
brother was found to be compatible through human
leukocyte antigen typing and donated allogeneic
hematopoietic stem cells for transplantation. This com-
bination of therapies helped the patient achieve strin-
gent complete response upon receiving thalidomide
maintenance therapy. If we had not found del(17p),
treatment would have instead involved iso-allogeneic
stem cell transplantation.
These two cases provide evidence that our microflu-
idic-based MF-CD45-TACs can be used to improve
diagnosis, risk stratification, and management of
patients with MM for better treatment outcomes. In
light of literature showing that genetic profiling is an
important factor affecting a variety of treatment out-
comes, we have developed a rapid, simple, and sensi-
tive assay for clinical applications.
Table 1. Demographic and clinical characteristics of the patients.a
Characteristic
Classic
selection
group
(N = 48)
Microfluidic
selection
group
(N = 48)
Age (year), no. Median 60 60
Range 41–78 41–78
Body weight (kg) Median 61.5 61.5
Range 42–75 42–76
Sexb, n (%) Male 33 (69) 33 (69)
Female 15 (31) 15 (31)
Diagnosis:
Stage, n (%)
I 10 (20.8) 10 (20.8)
II 14 (29.2) 14 (29.2)
III 24 (50) 24 (50)
CD38+/CD138+, %b 10.3  8.5 37.7  20.4
Cytogenetic
abnormality, n (%)
IgH 11 (22.9) 27 (56.3)
13q14 6 (12.5) 18 (37.5)
17p- 3 (6.25) 11 (22.9)
1q21 9 (18.8) 20 (41.7)
Disease risk, n (%)c
(FISH for risk
stratification)
Low-risk 5 (10) 9 (19)
Intermediate-
risk
38 (80) 27 (56)
High-risk 5 (10) 12 (25)
aThe chi-square test was used for categorical variables, and analy-
sis of variance.
bP < 0.001 for the difference in the distribution of characteristics
among the two groups.
cDisease risk was categorized as low, intermediate, high, as previ-
ously described. (Rajkumar, 2016) P < 0.01 for the difference in
the distribution of characteristics among the two groups.
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4. Discussion
Classic diagnosis of MM requires at least 10% of the
cells in bone marrow to be PCs or a biopsy-proven
plasmacytoma plus evidence of one or more MM
defining events (Rajkumar, 2016). Molecular classifica-
tion shows that MM is a highly heterogeneous PC
population with several different cytogenetically dis-
tinct PC malignancies, including gain(1q), del(1p), del
(17p), del(13), RAS mutations, and secondary translo-
cations involving Myc – all of which can influence dis-
ease course, response to therapy, and prognosis
(Rajkumar, 2016). Accurate risk stratification, as
determined by cytogenetic abnormalities, is considered
to be the most important prognostic factor essential to
guiding individual treatment of MM (Kapoor et al.,
2010). Despite existing guidelines recommending close
observation until progression to symptomatic disease,
clinical studies have confirmed that early treatment
can improve overall survival rates for high-risk
patients. Cytogenetics and molecular genetics can help
in the early assessment of risk; thus, more sensitive
and accurate screening methods like ours may benefit
these patients.
Although cytogenetic abnormalities can be identified
by fluorescence in situ hybridization (FISH), the rarity
and uneven distribution of myeloma cells in the bone
marrow often results in high false-negative rates.
MACS is recommended to enrich myeloma PCs (Fon-
seca et al., 2009), but is expensive, requires a large vol-
ume of bone marrow, and is a time-consuming and
laborious procedure, resulting in inconsistency (Chen
et al., 2007). Here, we provide a microfluidic MF-
CD45-TAC enrichment scheme, allowing rapid
Fig. 3. Improved clinical outcomes with microfluidic CD45 depletion (Patient 1). (A) bone marrow smear at the time of initial diagnosis. PC
abnormalities increased, showing clustered or scattered distribution, with mainly mature and naive cells and similar body size. Coarse
chromatin, rich cytoplasm, and tumorlike prominence were observed in the nucleus. (B) Bone marrow smear after effective treatment
(complete remission). Active bone marrow hyperplasia, granulocyte, and erythroid cells were observed at all stages; the whole PCs were
rare, with normal morphology and no typical abnormal PCs. (C) Flow cytometry without microfluidic enrichment. PCs (CD38+CD138+) were
only 4.21%, and no FISH cytogenetic abnormalities were found (low-risk). (D) After microfluidic enrichment (center inset), PCs (CD38+/
CD138+) increased to 36.17%. (E) FISH on enriched PCs showed 17p- (red: D13S319; green: P53). (F) FISH showed del(13q14) in enriched
PCs (red: D13S319; green: RB1). The patient was reclassified and treated as having high-risk MM. Treatment led to complete remission.
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enrichment of PCs, thereby improving accuracy of risk
stratification through more sensitive cytogenetic detec-
tion, improving patient prognosis.
Our study resonates with the established AJH and
IMWG criteria: patients with del(17p), t(14;16), and t
(14;20) have high-risk MM (Rajkumar, 2016). Patients
with t(4;14) translocation and gain(1q) have intermedi-
ate risk. All others are considered standard risk. Initial
treatment for those not in the high-risk group consists
of bortezomib, lenalidomide, and dexamethasone
(VRD). In high-risk patients, carfilzomib, lenalido-
mide, and dexamethasone is an alternative to VRD.
This initial therapy is followed by autologous stem cell
transplantation (Ludwig et al., 2013).
In this study, we used MF-CD45-TACs to improve
the detection rate of cytogenetic abnormalities in
newly diagnosed patients with MM. As demonstrated
by the two example cases showed above, MF-CD45-
TACs can improve risk stratification of MM and
impact clinical outcomes. Thus, we provide a novel,
sensitive assay for diagnosis, risk stratification, and
management of patients with MM. Further large-scale
clinical randomized controlled trials are needed to
determine whether the change in clinical treatment reg-
imens can lead to prolonged overall survival and
improved quality of life.
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